Skip to content

E-learning to Improve Oral Anticoagulant Use in Hospitalized Older People With AF

Simulation-based Technologies to Improve the Appropriate Use of Oral Anticoagulants in Hospitalized Elderly Patients With Atrial Fibrillation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03188211
Acronym
SIM-AF
Enrollment
247
Registered
2017-06-15
Start date
2017-09-01
Completion date
2018-09-30
Last updated
2018-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulant Drugs, Atrial Fibrillation, Drug Prescriptions, Elderly, Geriatrics, Internal Medicine, Simulation Training

Brief summary

Atrial Fibrillation (AF) is the most common cardiac arrhythmia and the main cause of cardioembolic stroke. Oral Anticoagulation (OAC) has been shown to significantly prevent AF-related thromboembolism, however, despite convincing evidences and current guidelines recommendations, OAC tends to be underused in clinical practice especially in the oldest. Education and training to appropriately select people suitable for OAC for stroke prevention could be pivotal in the decision making process. According to the study project, physicians working in Internal Medicine and Geriatric wards, where are mainly admitted elderly people with AF, will undergo to a program of e-learning through computer-based simulation method reproducing clinical scenarios of patients aged 65 years or older, with known or newly diagnosed AF, admitted to hospital for any medical reason and requesting that a decision about long-term antithrombotic therapy is taken. Primary objective of the study is to investigate whether such educational intervention will improve the appropriate use and prescription rate of OAC in hospitalised elderly patients with AF, multimorbidity and polypharmacy, in comparison to the usual practice. The study will be a cluster randomised controlled trial involving a network of Internal Medicine and Geriatrics wards. Thirty-two wards will be recruited based on voluntary participation and randomised to receive an educational intervention through computer-based simulation, (N=16) or to continue with the usual practice (N=16). Subjects receiving the intervention will be all the staff physicians of the wards randomised in the intervention arm. The impact of the intervention compared with the usual practice will be evaluated in patients aged 65 years or older admitted to the participating centres with a known diagnosis of AF or newly diagnosed with AF during the hospitalisation.

Interventions

OTHERE-learning educational program

A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.

OTHERControl

Any educational program will be delivered to clinicians assigned to control arm

Sponsors

Mario Negri Institute for Pharmacological Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Intervention model description

cluster randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* subjects 65 years of age or older, with known or newly diagnosed AF, admitted to the Internal Medicine and Geriatric wards of the REPOSI network, * consent to participate to the study.

Exclusion criteria

* consent denial to participate to the study, * absolute contraindication to OAC, * re-hospitalisation for the subject already included in the study, * life expectancy less than 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Elderly with AF prescribed with OACthrough study completion, up to 1 yeardifference in the proportion of elderly patients with AF prescribed with OAC between the post-intervention and the pre-intervention observational phase

Secondary

MeasureTime frameDescription
Total duration of connection to Dr Sim1 monthaverage total duration of connection to Dr. Sim among the phsyicians of the centres randomised to the intervention during the 1 month intervention phase
Elderly patients with AF prescribed with any antiplatelet agentthrough study completion, up to 1 yeardifference in the proportion of elderly patients with AF prescribed with any antiplatelet agent (and not OAC) between the post-intervention and the pre-intervention observational phase
Elderly patients with AF newly prescribed with OAC agentsthrough study completion, up to 1 yeardifference in the proportion of elderly patients with AF prescribed with new OAC agents between the post-intervention and the pre-intervention observational phase
Number of access to Dr Sim1 monthaverage number of access to Dr. Sim among the phsyicians of the centres randomised to the intervention during the 1 month intervention phase
Re-hospitalization rate6 month follow upproportion of patients re-hospitalised for any cause during the 6 months after the hospital discharge
Minor bleeding events6 month follow upproportion of patients experiencing a minor bleeding event during the 6 months after hospital discharge)
Major bleeding event6 month follow upproportion of patients experiencing a major bleeding event during the 6 months after hospital discharge)
Patients experiencing any cerebro or cardiovascular events6 month follow upproportion of patients experiencing any stroke, transient ischaemic attack (TIA), other major arterial or venous thromboembolism during the 6 months after the hospital discharge

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026